InfectoPharm Arzneimittel und Consilium GmbH

InfectoPharm Arzneimittel und Consilium GmbH is a leading medium-sized pharmaceutical manufacturer in the field of pediatric medicine. The company, founded in 1988, has garnered recognition from the medical community with accolades such as the "Golden Tablet" and from the business realm as the "Most Crisis-Resilient Employer 2022" and "Most Crisis-Resilient Company 2023" by Creditreform. With 36 years of experience, InfectoPharm has been dedicated to developing medicines with genuine added value, constantly seeking better treatment methods. Besides its commitment to innovation, InfectoPharm places emphasis on its work culture and employee well-being, offering a range of benefits including attractive compensation, flexible work hours, home office opportunities, personalized training, a company-owned childcare facility, subsidized employee restaurant featuring local products, company-sponsored sports initiatives, and more. The company presents a sustainable growth and earnings strength, with an annual turnover of approximately €250 million, a figure that directly benefits its around 300 employees through various incentives and profit-sharing opportunities. InfectoPharm's extensive product and service portfolio positions it as a leading player in pediatric healthcare in Germany, distributing a significant number of preparations internationally through its subsidiary Pädia, with presences in Austria, Italy, and France. The company has demonstrated its commitment to collaborative success, fostering respectful collaboration, short decision-making processes, and mutual goal achievement. More information can be found at www.jobs.infectopharm.de.